ValiRx plc (VAL.L) Research

ValiRx plc is a UK-based biopharmaceutical company dedicated to pioneering oncology therapeutics and companion diagnostics. Among its primary drug candidates is VAL201, a small molecule that has progressed through Phase I/II trials, aiming to treat prostate cancer and other hormone-dependent solid tumors, including breast and ovarian cancer. Another key candidate, VAL401, a reimagined version of the antipsychotic drug risperidone, has successfully completed Phase II clinical trials for addressing non-small cell lung cancer. The company's pipeline also features VAL301, a peptide currently in pre-clinical development for treating endometriosis in women. Additionally, BC201, a compound combining the peptide ingredient from VAL201/VAL301 with complementary active components, is being developed to alleviate severe symptoms of COVID-19. ValiRx plc was established in 2000 and is headquartered in Hatfield, United Kingdom.

Market snapshot

Symbol
VAL.L
Price
$0.19
Day change
0.00%
Market cap
$692.5K
P/E ratio
-0.39x
52-week range
0.17-0.849
Sector
Healthcare
Industry
Biotechnology
Next earnings
in 3 months

Peer companies

  • Cizzle Biotechnology Holdings Plc (CIZ.L)
  • CRISM Therapeutics Corporation (CRTX.L)
  • Feedback plc (FDBK.L)
  • Futura Medical plc (FUM.L)
  • Genedrive Plc (GDR.L)
  • Nuformix plc (NFX.L)
  • Physiomics Plc (PYC.L)
  • Roquefort Therapeutics plc (ROQ.L)

Open ValiRx plc (VAL.L) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.